MASSMATRIX, INC.

Columbus, OH

OncologyGrant-only

What changed

NIH R41 · $0.3M · Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids

Apr 2025New grantApr 17, 2025Source filing (opens the source filing in a new tab)

Momentum

30no change

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

15,632 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R41 · $317k · non-dilutive
May 1, 2025
MASSMATRIX, INC. · PI FREITAS, MICHAEL A. · NIGMS · award ends Apr 30, 2026 · Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids
NIH RePORTER · NIH RePORTER 11068509 (opens the source filing in a new tab)
Grant
P30 · $221k · non-dilutive
Sep 12, 1997
OHIO STATE UNIVERSITY · PI FREITAS, MICHAEL A. · NCI · award ends Nov 30, 2025 · Shared Resource 14: Proteomics (PSR)
NIH RePORTER · NIH RePORTER 11000376 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.24no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Michael A. Freitas

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R41 · $0.3M · Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids
Apr 2025New grantSource (opens the source filing in a new tab)
NIH P30 · $0.2M · Shared Resource 14: Proteomics (PSR)
Apr 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

R41 · $317k · non-dilutive

P30 · $221k · non-dilutive